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Background:With the US Food andDrug Administration approval of the TAG thoracic device, more thoracic pathologies
are being treated using endovascular techniques. Although endovascular abdominal and thoracic aortic repairs have some
apparent similarities, there are substantive anatomic, pathologic, and technical differences that could impact perioperative
outcomes. The purpose of this study is to identify these differences.
Methods: During a 5-year period, 121 endovascular thoracic aortic repairs (TEVAR) and 450 abdominal aortic repairs
(EVAR) were performed at a single institution. Preoperative, intraoperative, and early postoperative data were
prospectively collected and retrospectively reviewed. Aggregate outcome measures were compared between the two
cohorts, with statistical significance achieved at P < .05.
Results: The mean age of patients undergoing EVAR was 72.8  8.3 compared with 68.3  13.9 for TEVAR (P  .02).
More women underwent TEVAR (30.6% vs 11.1%, P< .001). Aneurysms undergoing TEVARwere larger than those for
EVAR (62.0 mm vs 58.3 mm, P  .01). Intraoperatively, EVAR required 26.2 minutes of fluoroscopy compared with
22.1 minutes for TEVAR (P < .001). The amount of contrast used was higher in TEVAR (133.6 mL vs 93.6 mL, P <
.001). The mean procedure times were 164 minutes for EVAR and 115 minutes for TEVAR (P < .001). Iliac conduits
were required in 46 patients (10.2%) undergoing EVAR, and in 24 (19.8%) undergoing TEVAR (P .007). The 30-day
or in-hospital mortality was 2.0% for EVAR and 5.0% for TEVAR (P  NS). The median length of stay was longer for
TEVAR (3 days vs 2 days, P .034). There were 54 postoperative complications in 36 TEVAR patients (29.8%),
including 13 neurologic (10.7%), 8 renal (6.6%), 7 pulmonary (5.8%), 6 ischemic (5.0), and 5 (4.1%) hemorrhagic events.
Among the EVAR group, 136 (30.2%) patients had postoperative complications, which included 45 ischemic (10.0%), 34
wound (7.6%), 22 renal (4.9%), 12 cardiac (2.7%), 8 pulmonary (1.8%), 5 gastrointestinal (1.1%), and 4 neurologic (0.9%)
events.
Conclusions: A relatively higher proportion of women underwent TEVAR than EVAR, and this was reflected in the
greater need for iliac conduits to accommodate the larger delivery catheters of the thoracic devices. Intraoperative imaging
techniques were also different, and TEVAR required higher contrast volumes despite shorter overall procedure times.
The incidence of strokes and spinal cord ischemia was also higher during TEVAR. Despite apparent similarities of devices
and techniques, EVAR and TEVAR are fundamentally different procedures with different perioperative outcomes.
(J Vasc Surg 2007;45:86-9.)Endovascular repair (EVAR) of abdominal aortic aneu-
rysm (AAA) has become a standard of care. Although its
long-term success remains largely unknown, early results
appear to be superior to that of conventional open surgical
repair,1 with significantly lower perioperative morbidity2
and mortality for both intact3 and ruptured AAA.4
Open thoracic aortic repairs historically have been as-
sociated with high morbidity and mortality.5,6 Despite
adjunctive techniques such as cerebrospinal fluid drainage,
cardiopulmonary bypass, and shunting to provide distal
perfusion,7-9 pulmonary and neurologic complications re-
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86main significant. If we extrapolate the early benefits of
EVAR, endovascular thoracic aortic repair (TEVAR) may
potentially offer significant reductions in the mortality and
morbidity associated with open thoracotomy and aortic
cross-clamping.
In the current study, we compared the perioperative
differences between endovascular abdominal and thoracic
aortic repairs. Although many of the techniques of these
two endovascular therapies appear similar, we hypothesized
that anatomic and physiologic differences between the
thoracic and abdominal aorta and their respective endovas-
cular devices would demonstrate important differences in
perioperative outcomes.
METHODS
We retrospectively reviewed the records from our pro-
spectively maintained clinical database. All procedures were
performed at a single institution. Between 2000 and 2005,
we performed 121 thoracic and 450 abdominal aortic
endovascular repairs. The distribution of the different de-
vices is given in Table I. Preoperative, intraoperative, and
postoperative data were collected, including demographic
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tive morbidity and mortality.
Select definitions. For TEVAR, the maximum diam-
eter was dependent on the thoracic pathology: fusiform
aneurysm, (wall-to-wall) diameter, saccular aneurysm or
penetrating ulcer; maximum diameter or ulcer depth, in-
cluding the aortic lumen at that location, transection, or
pseudoaneurysm; diameter of the hematoma, and dissection
(acute and chronic); and maximum diameter inclusive of the
true and false lumens. Neurologic complications included
transient or permanent cerebral hemispheric events and
spinal cord ischemia.
Statistical analysis. Data are reported as mean stan-
dard deviation for normalized data, or median for non-
normalized data. Statistical differences were detected using
a t test for normalized data,Mann-Whitney rank sum test to
detect differences in median values, and 2 analysis for
tabulated data. Significance was achieved at P  .05.
RESULTS
The mean age was 72.8  8.3 years (range, 49 to 95
years) for EVAR and 68.3  13.9 years (range, 16 to 92
years) for TEVAR (P .02). A relatively higher proportion
of women underwent TEVAR (M/F, 84:37, 30.6%) than
EVAR (M/F, 400:50, 11.1%, P .001). A higher propor-
tion of patients undergoing TEVARwere classified as Amer-
ican Anesthesiologist Society class IV. The demographics and
preoperative comorbidities are listed in Table II.
Although all of the EVAR were for aneurysms, TEVAR
Table I. Distribution of abdominal and thoracic
endograft devices
IDE clinical trial,
n (%)a
Postapproval,
n (%) Total
EVAR
AneuRxb 0 (0) 177 (100) 177
Zenithc 0 (0) 125 (100) 125
Excluderd 0 (0) 121 (100) 121
Vanguarde 12 (100) 0 (0) 12
Ancuref 0 (0) 11 (100) 11
TriVascularg 4 (100) 0 (0) 4
Total 16 (3.6) 434 (96.4) 450
TEVAR
TAGd 26 (28.9) 64 (71.1) 90
Talentb 19 (100) 0 (0) 19
TX2c 7 (100) 0 (0) 7
Zenith Cuffc 0 (0) 3 (100) 3
AneuRx Cuff1b 0 (0) 2 (100) 2
TOTAL 52 (43.0) 69 (57.0) 121
IDE, Investigational device exemption; EVAR, endovascular abdominal
aneurysm repair; TEVAR, thoracic endovascular aneurysm repair.
aOverall, 2.7% of EVAR and 43.0% of TEVAR patients were enrolled in an
IDE clinical trial.
bMedtronic Vascular, Santa Rosa, Calif.
cCook Endovascular, Bloomington, Ind.
dW. L. Gore & Associates, Flagstaff, Ariz.
eBoston Scientific, Natick, Mass.
fGuidant, Menlo Park, Calif.
gTriVascular, Santa Rosa, Calif.involved a wider range of aortic pathologies. TEVAR casesincluded 69 aneurysms (57.0%), 23 penetrating ulcers
(19.0%), 13 dissections (10.7%), 5 traumatic injuries (4.1%),
and a variety of other conditions including intramural hema-
tomas and diffuse atheromatous disease, among others, in 11
patients (9.1%). Thirty TEVAR patients (24.8%) had previous
infrarenal aortic reconstruction. Of the TEVAR cases, 76.9%
were performed electively vs 92.0% of the EVAR proce-
dures (P  .001); conversely, 13.2% of TEVAR were
performed urgently for symptomatic but intact aortas and
9.9% for aortic rupture, compared with 4.4% (P  .008)
and 3.6% (P  .001) of EVAR cases, respectively. The
mean maximal diameter for EVAR was 58.3  11.8 mm,
which was smaller compared with 62.0  14.7 mm for the
subset of 92 TEVAR patients (76%) with aneurysms and
penetrating ulcers (P  .01).
Intraoperatively, TEVAR required significantly less
procedural time (115  56 minutes vs 164  76 minutes;
P .001). Total fluoroscopy time for TEVARwas similarly
less than for EVAR (22.1  13.8 minutes vs 26.2  12.6
minutes; P .001); however, the amount of contrast used
was greater for TEVAR (133.6  49.8 mL vs 93.6  34.8
mL; P .001). The median blood loss was similar for each
group at 200 mL (P  NS).
Iliac conduits were required in 24 TEVAR patients
(19.8%) compared with 46 EVAR patients (10.2%; P 
.007). More women required iliac conduits than men for
both TEVAR (14.9% vs 7.1%, P .001) and EVAR (42.0%
vs 6.3%, P  .001). Perioperative access-related complica-
tions were seen in 13 TEVAR patients (10.7%), involving
13.5% of the women and 9.5% of the men (PNS), and in
57 EVAR patients (12.7%), involving 34% of the women
and 10% of the men (P  .001).
The median length of stay for EVAR was 2 days (range,
Table II. Patient demographics and comorbidities
Demographics TEVAR n  121 (%) EVAR n  450 (%)
Age (mean  SD)* 68.3  13.9 72.8  8.3
Female* 37 (30.6) 50 (11.1)
ASA
III 60 (49.6) 308 (68.4)
IV* 57 (47.1) 121 (26.9)
Comorbidities
HTN 72 (59.5) 293 (65.1)
Tobacco abuse 54 (44.6) 245 (54.4)
CAD* 29 (24.0) 207 (46.0)
Hyperlipidemia 39 (32.2) 165 (36.7)
COPD 22 (18.2) 124 (27.6)
CVOD* 7 (5.8) 79 (17.6)
CRI 22 (18.2) 72 (16.0)
PVOD* 9 (7.4) 72 (16.0)
DM 20 (16.5) 60 (13.3)
TEVAR, Thoracic endovascular aneurysm repair; EVAR, endovascular ab-
dominal aneurysm repair; ASA, American Society of Anesthesiologists;
HTN, hypertension;CAD, coronary artery disease;COPD, chronic obstruc-
tive pulmonary disease; CVOD, cerebrovascular occlusive disease; CRI,
chronic renal insufficiency; PVOD, peripheral vascular occlusive disease;
DM, diabetes mellitus.
*P  .05.1 to 61 days) compared with 3 days for TEVAR (range, 1 to
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days among TEVAR patients who had iliac conduits was
identical to those who did not. The 30-day or in-hospital
mortality rates were 2.0% for EVAR and 5.0% for TEVAR
(P  .137).
The overall 29.8% morbidity rate for TEVAR was not
significantly different from the 30.2% for EVAR (P  NS);
however, the nature of the complications was significantly
different (Fig). EVAR patients were more likely to have
wound complications (1.7% vs 7.6%, P  .031), whereas
TEVAR patients had a higher incidence of neurologic
(10.7% vs 0.9%, P  .001) and pulmonary complications
(5.8% vs 1.8%, P  .033). Specifically, four neurologic
complications occurred EVAR patients: three (0.7%)
strokes and one (0.2%) spinal cord ischemia.
In addition, among those who had regional anesthesia,
there was a 2.0% incidence of significant spinal headaches
from dural leaks. For TEVAR, there were eight instances of
spinal cord ischemia (6.6%) and five strokes (4.1%). The
rates of spinal cord ischemia between those who had prior
abdominal aortic repairs and those who did not were similar
(6.7% vs 6.6%, P  NS). Indeed, only two of the eight
TEVAR patients with spinal cord ischemia had prior ab-
dominal aortic surgery. Eleven patients had spinal drains (3
preoperatively per physician preference, 8 postoperatively).
Although none of the three patients with preoperative
drainage had spinal cord ischemia, spinal drainage was
associated with an overall longer median length of stay (5 vs
3 days, P  .017).
DISCUSSION
The substantive differences between TEVAR and
EVAR belie the apparent similarities of the two therapies.
Most significantly, TEVAR patients represent a vastly more
heterogeneous cohort in terms of demographics, pathol-
ogy, and clinical presentation. This very heterogeneity,
Fig. Relative incidences of complications between endovascular
abdominal aneurysm repair (EVAR) and thoracic endovascular
aneurysm repair (TEVAR). (*P  .05)compared with the relative homogeneity of the EVARcohort, is an important and pertinent characteristic that
served as the primary motivation for this study.
Mechanistically, everything in the thoracic aorta is
more remote from the entry point of guidewires, catheters,
and delivery systems. This means longer catheters and
wires, with reduced torque control and pushability. This
physical distance is compounded by serial iliac, abdominal,
and thoracic aortic tortuosity, most commonly present in
the supradiaphragmatic segment and near the apex of the
arch. Significant motion of the thoracic aorta can also occur
during respiratory and cardiac cycles. All of these factors
make precise deployment of the devices near the delimiting
branch vessels (proximally: left subclavian or left common
carotid arteries; distally: celiac artery) significantly more
challenging than in the abdominal aorta.
The recently published results of the Gore TAG pivotal
trial (W. L. Gore & Assoc, Phoenix, Ariz) showed that
endovascular repair for descending thoracic aortic aneu-
rysms was associated with 32% morbidity, 1.5% mortality,
and a 97% rate for 2-year freedom from aneurysm-related
death.10 The 5% mortality of TEVAR vs 2% of EVAR
patients in our study likely represents the greater prevalence
of comorbidities and the higher incidence of emergent and
urgent cases amongst the TEVAR group.
This study highlighted some of the key differences in
the types of morbidities and periprocedural measures.
TEVAR required larger contrast volumes compared with
EVAR, despite shorter fluoroscopy times. This was due to
the larger boluses per injection used to adequately image
the thoracic aorta. In addition, more patients required iliac
conduits. Postoperatively, TEVAR patients had a longer
hospitalization and higher mortality, although the latter
did not reach statistical significance. TEVAR was also asso-
ciated with a higher incidence of neurologic and pulmonary
complications but a lower incidence of wound complica-
tions.
The demographics of those presenting with thoracic
pathologies tended to be more diverse than the abdominal
cohort in this study. The variance in pathologies may
explain the younger age of the TEVAR group, because
patients presenting with dissections and traumatic transec-
tions are typically younger than those who have degenera-
tive atherosclerotic pathologies. Only 11% of EVAR pa-
tients were women compared with 31% of TEVAR patients.
Women tend to have smaller diameter peripheral arteries,
and this likely resulted in more access-related complica-
tions.11 Adding to the access difficulties are the larger
delivery systems required for thoracic devices compared
with abdominal devices. This combination likely resulted in
almost twice the number of TEVAR patients requiring iliac
conduits compared with EVAR. The incidence of iliac
conduits in our thoracic cohort was similar to that pub-
lished in the TAG clinical trial.10
TEVAR was associated with a significantly increased
risk of neurologic morbidity, including strokes and spinal
cord ischemia, than EVAR. Other series have reported
stroke and paraplegia rates of 7% and 3% after TEVAR,12and the TAG pivotal trial reported respective rates of 4%
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for spinal cord ischemia after TEVAR remain inconclusive,
the relatively greater extent of aortic coverage and blockage
of vertebral collateral to the anterior spinal artery, as well as
a nearly 25% incidence of prior aortic repairs are likely
contributory.
In particular, the difference between the rates of spinal
cord ischemia of in our study and the TAG pivotal trial may
be due to the sheer heterogeneity of the respective cohorts
in terms of pathologies (TAG: fusiform and saccular aneu-
rysms only), physiology (TAG: good surgical risk only),
and clinical presentation (TAG: intact aneurysms under-
going elective repairs only). The TEVAR group in our
study included emergent cases, such as ruptures and
acute complicated dissections, with associated hypoten-
sion and acidosis. Although these factors were not spe-
cifically examined, perioperative hemodynamic instabil-
ity has been recognized as another potential etiology of
spinal cord ischemia.
It is well established that routine spinal drainage is
protective against spinal cord ischemia during open tho-
racic aortic surgery, but it is presently unknown whether
this effect holds true during endovascular repair. The three
patients in our study who had preoperative drainage did not
have spinal cord ischemia, but the numbers are too small to
draw any conclusions.
In the absence of clear evidence, therefore, it has not
been our practice to prophylactically place spinal drains in
patients undergoing TEVAR, regardless of prior abdominal
aortic surgery or planned extent of aortic coverage. When a
patient shows clinical signs of spinal cord ischemia, our
protocol involves elevation of blood pressure (systolic
160 mmHg, mean arterial pressure100 mmHg) with
fluid and dopamine infusions and expeditious placement of
spinal catheter. The catheter is drained at a height of 10 cm
H2O for 48 hours, a trial capping of the drain for an
additional 24 hours to make sure that there is no subse-
quent neurologic deterioration, followed by drain removal.
If no neurologic improvement is noted within the first 48
hours, an additional 24 hours of drainage is attempted, and
then the drain removed. Emergent drains were placed
postoperatively under this protocol in all eight of the
TEVAR patients with spinal cord ischemia. Only one had a
permanent deficit, and the rest had complete reversal of
their lower extremity symptoms.
CONCLUSION
Endovascular stent graft repair of the thoracic aorta has
provided a useful treatment option for a diverse array of
pathologies. Although the findings of this study may be
self-evident to an experienced endovascular therapist famil-
iar with both procedures, endovascular treatment of the
thoracic aorta remains relatively new for many operators
whose experience may be limited to the endovascular repair
of the abdominal aorta or surgical repair of the thoracic
aorta, and who may not fully appreciate many of the tech-
nical nuances of this particular therapy. By direct compari-son of two unselected, consecutive cohorts, this study
highlights the differences of the two therapies in real prac-
tice and that expertise in one does not necessarily translate
into expertise in the other, and each should be approached
cautiously on its own merits.
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